Ardelyx (ARDX) Revenue Growth (1y) (2014 - 2026)
Ardelyx (ARDX) Revenue Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 96.43% |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | 27.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.47% |
| Dec 31, 2025 | 7.82% |
| Sep 30, 2025 | -96.54% |
| Jun 30, 2025 | 33.38% |
| Mar 31, 2025 | 61.04% |
| Dec 31, 2024 | 237.95% |
| Sep 30, 2024 | 74.21% |
| Jun 30, 2024 | 227.86% |
| Mar 31, 2024 | 304.81% |
| Dec 31, 2023 | -22.22% |
| Sep 30, 2023 | 1,030.99% |
| Jun 30, 2023 | 784.13% |
| Mar 31, 2023 | 2,329.27% |
| Dec 31, 2022 | 4,193.29% |
| Sep 30, 2022 | 325.06% |
| Jun 30, 2022 | 92.38% |
| Mar 31, 2022 | -92.89% |
| Dec 31, 2021 | -43.12% |
| Sep 30, 2021 | -56.76% |
| Jun 30, 2021 | -28.49% |